EMPA-Kidney Seals SGLT2 Inhibitors as ' Foundational ' for CKD EMPA-Kidney Seals SGLT2 Inhibitors as ' Foundational ' for CKD

Empagliflozin ' s efficacy in a range of patients with chronic kidney disease in EMPA-Kidney filled evidence gaps and confirmed SGLT2 inhibitors as a key treatment regardless of diabetes status.Medscape Medical News
Source: Medscape Pulmonary Medicine Headlines - Category: Respiratory Medicine Tags: Nephrology News Source Type: news